National Institute on Deafness and Other Communication Disorders (NIDCD)
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, National Institute on Deafness and Other Communication Disorders (NIDCD) sits in the top decile of US sponsors by registered trial count (#484 of 15,742 sponsors by registered trial count).
National Institute on Deafness and Other Communication Disorders (NIDCD): 34 sponsored US clinical trials, 6 recruiting.
National Institute on Deafness and Other Communication Disorders (NIDCD) sponsors 34 registered US clinical trials on ClinicalTrials.gov, 6 of them currently recruiting, and 18 completed. 6 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hearing Loss, with 4 trials.
Top-decile sponsor footprint
National Institute on Deafness and Other Communication Disorders (NIDCD) ranks in the top decile of sponsors by registered trial count (#484 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
18 of 28 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (64.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
34 total, page 1 of 1
Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
NCT04915183
NIDCD Otolaryngology Clinical Protocol Biospecimen Bank
NCT06303180
Collection of Clinical Data and Specimens for Research in Hearing, Balance, Taste, Smell, Voice, Speech, and Language Disorders.
NCT05670496
Deep Phenotyping of Hearing Instability Disorders: Cohort Establishment, Biomarker Identification, Development of Novel Phenotyping Measures, and Discovery of Therapeutic Targets
NCT04806282
Natural History of Autosomal Dominant Hearing Loss
NCT04501081
Normal Values in Hearing and Balance Testing
NCT01629108
Collection of Clinical Data and Specimens for Research on Head and Neck and Communication Disorders
NCT04618432
Hearing Loss and the Effects of Statin Drugs in People With Head and Neck Squamous Cell Carcinoma Treated With Cisplatin Chemoradiation
NCT03225157
Connectivity Analysis for Investigation of Auditory Impairment in Epilepsy
NCT01212068
Studies of Measures of Attention
NCT00776737
Brain Imaging of Tinnitus
NCT00359931
Effects of Sleep Deprivation and Recovery on Cognitive Functions
NCT00179322
Genetic Linkage Studies of Stuttering
NCT00001604
Genetic Analysis of Hereditary Disorders of Hearing and Balance
NCT00023049
Surgery for Vocal Cord Paralysis
NCT00064571
A Comparison of Language Intervention Programs
NCT00033150
Dopamine Function in Developmental Stuttering
NCT00024960
Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts
NCT00023036
Study of Taste Deficits
NCT00022997
Vaccine Therapy in Treating Patients With Stage IV Head and Neck Cancer
NCT00021424
Patient Evaluation for Head and Neck Surgery Branch Studies
NCT00011492
Maternal Immunization To Prevent Infant Otitis Media
NCT00617682
Genetic Studies of Tone Deafness
NCT00006076
Testing a Possible Cause of Reduced Ability of Children to Process Speech in Noise
NCT00001957
Hereditary Deficits in Auditory Processing Leading to Language Impairment
NCT00004570
Autoimmunity in Inner Ear Disease
NCT00000361
Genetic Analysis of Human Hereditary Hearing Impairment
NCT00001606
Vaccination for Middle Ear Infection
NCT00001605
Adenoidectomy for Otitis Media in 2-3 Year Old Children
NCT00016497
The Effects of Upper Airway and Digestive Tract Tumors on the Immune System
NCT00001603
Genetic Factors Related to Stuttering
NCT00001602
Central Mechanisms in Speech Motor Control Studied With H215O PET
NCT00001308
Acute Otitis Media: Adjuvant Therapy to Improve Outcome
NCT00000363
Randomized Study of Two Interventions for Liquid Aspiration: Short-Term and Long-Term Effects
NCT00000362
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 1 |
| Phase 3 | 6 |
Therapeutic Areas
What is open in the National Institute on Deafness and Other Communication Disorders (NIDCD) pipeline
6 recruiting of 34 indexed (18% open); 18 completed (53%).
Phase mix: 6 late (III/IV) vs 4 early (I/II) (balanced across stages).
Top condition: Hearing Loss (4 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Institute on Deafness and Other Communication Disorders (NIDCD): open-pipeline peers nationwide
Peers matched on 34 registered trials and 18% open enrollment, not the therapeutic-area sidebar.
National Institute on Deafness and Other Communication Disorders (NIDCD) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 34 trials (± recruiting share)
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · 34 trials · 38% recruiting
- American Regent · 34 trials · 0% recruiting
- Amicus Therapeutics · 34 trials · 15% recruiting
- Cochlear · 34 trials · 12% recruiting
Sponsors near 18% open enrollment (± trial volume)
- ConvaTec · 18% recruiting · 17 trials
- Endologix · 18% recruiting · 17 trials
- NICHD Pelvic Floor Disorders Network · 18% recruiting · 17 trials
- Sanford Health · 18% recruiting · 34 trials
Related
What to do with this National Institute on Deafness and Other Communication Disorders (NIDCD) page
34 registered trials is a research-attention snapshot, not an endorsement of National Institute on Deafness and Other Communication Disorders (NIDCD) or any single study.
- 6 of National Institute on Deafness and Other Communication Disorders (NIDCD)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Hearing Loss is the condition National Institute on Deafness and Other Communication Disorders (NIDCD) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hearing Loss trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
National Institute on Deafness and Other Communication Disorders (NIDCD) pipeline card: 34 registered trials from official public datasets.Report a data error.